JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 2, 2006; DOI: 10.1124/jpet.106.110411


0022-3565/07/3201-162-172$20.00
JPET 320:162-172, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.106.110411v1
320/1/162    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Claydon, T. W.
Right arrow Articles by Fedida, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Claydon, T. W.
Right arrow Articles by Fedida, D.

NEUROPHARMACOLOGY

4-Aminopyridine Prevents the Conformational Changes Associated with P/C-Type Inactivation in Shaker Channels

Thomas W. Claydon, Moni Vaid, Saman Rezazadeh, Steven J. Kehl, and David Fedida

Departments of Anesthesiology, Pharmacology & Therapeutics (T.W.C., D.F.) and Cellular and Physiological Sciences (M.V., S.R., S.J.K.), University of British Columbia, Vancouver, British Columbia, Canada

The effect of 4-aminopyridine (4-AP) on Kv channel activation has been extensively investigated, but its interaction with inactivation is less well understood. Voltage-clamp fluorimetry was used to directly monitor the action of 4-AP on conformational changes associated with slow inactivation of Shaker channels. Tetramethylrhodamine-5-maleimide was used to fluorescently label substituted cysteine residues in the S3-S4 linker (A359C) and pore (S424C). Activation- and inactivation-induced changes in fluorophore microenvironment produced fast and slow phases of fluorescence that were modified by 4-AP. In Shaker A359C, 4-AP block reduced the slow-phase contribution from 61 ± 3 to 28 ± 5%, suggesting that binding inhibits the conformational changes associated with slow inactivation and increased the fast phase that reports channel activation from 39 ± 3 to 72 ± 5%. In addition, 4-AP enhanced both fast and slow phases of fluorescence return upon repolarization ({tau} reduced from 87 ± 15 to 40 ± 1 ms and from 739 ± 83 to 291 ± 21 ms, respectively), suggesting that deactivation and recovery from inactivation were enhanced. In addition, the effect of 4-AP on the slow phase of fluorescence was dramatically reduced in channels with either reduced (T449V) or permanent P-type (W434F) inactivation. Interestingly, the slow phase of fluorescence return of W434F channels was enhanced by 4-AP, suggesting that 4-AP prevents the transition to C-type inactivation in these channels. These data directly demonstrate that 4-AP prevents slow inactivation of Kv channels and that 4-AP can bind to P-type-inactivated channels and selectively inhibit the onset of C-type inactivation.


Received July 6, 2006; accepted September 29, 2006.

Address correspondence to: Dr. David Fedida, Department of Anesthesiology, Pharmacology and Therapeutics and Cellular and Physiological Sciences, 2350 Health Sciences Mall, Vancouver, BC V6T 1Z3, Canada. E-mail: fedida{at}interchange.ubc.ca




This article has been cited by other articles:


Home page
JGPHome page
M. Vaid, T. W. Claydon, S. Rezazadeh, and D. Fedida
Voltage Clamp Fluorimetry Reveals a Novel Outer Pore Instability in a Mammalian Voltage-gated Potassium Channel
J. Gen. Physiol., July 28, 2008; 132(2): 209 - 222.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.